Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the change in HbA1c in type 1 diabetes patients on Basaglar® (insulin glargine)?

In patients with type 1 diabetes, treatment with Basaglar provided a mean change in HbA1c of ‑0.35 at 24 weeks that was noninferior to that achieved with comparator insulin glargine 100 units/mL products.

US_cFAQ_BIV016_T1DM_CLINICAL_STUDY_HBA1C
US_cFAQ_BIV016_T1DM_CLINICAL_STUDY_HBA1C
en-US

Basaglar Clinical Study: Type 1 Diabetes

Adult patients with inadequately controlled type 1 diabetes participated in a 24-week, open‑label, active-controlled study with a 28-week extension to evaluate the glucose lowering effect of once-daily Basaglar® (insulin glargine) 100 units/mL compared with that of once-daily administration of another insulin glargine 100 units/mL product or a non-US-approved insulin glargine 100 units/mL product, both in combination with mealtime insulin lispro.1

Patient Characteristics

Characteristics of the 535 randomized patients included

  • 57.9% male
  • 74.5% Caucasian
  • 2.1% Black or African American
  • 4.3% American Indian or Alaskan native
  • 3.9% Hispanic
  • a mean age of 41.2 years
  • a mean body mass index of approximately 25.54 kg/m2
  • a mean duration of diabetes of 16.39 years, and 
  • 73.5% with a glomerular filtration rate >90 mL/min/1.73m2.1

Change in HbA1c

At week 24, treatment with Basaglar provided a mean reduction in glycated hemoglobin (HbA1c) that was noninferior to that achieved with comparator insulin glargine 100 units/mL products (Efficacy Results in Adult Patients With Type 1 Diabetes in a Phase 3 Clinical Study of Basaglar).1

Efficacy Results in Adult Patients With Type 1 Diabetes in a Phase 3 Clinical Study of Basaglar1

HbA1c, %

Basaglar + Insulin Lispro
(n=268)a

Comparator Insulin Glargine 100 Units/mL Productsb + Insulin Lispro
(n=267)

Baseline, mean

7.75

7.79

Change from baseline, adjusted meanc

-0.35

-0.46

Difference from comparator, adjusted mean (95% CI)c

0.11 (-0.002 to 0.219)

Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; HbA1c = glycated hemoglobin.

aIncludes 1 patient randomized to the Basaglar treatment group who was not included in the full analysis set.

bAnother insulin glargine 100 units/mL product and a non‑US‑approved insulin glargine 100 units/mL product.

cResults were calculated based on the number of patients in the full analysis set using their last observed postbaseline value of HbA1c. Observed HbA1c data at 24 weeks were available from 256 patients (95.5%) in the Basaglar treatment group and 258 patients (96.6%) in the comparator insulin glargine 100 units/mL treatment group.

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 21, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical